Hillengass J - Search Results

1

Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.

Klein U, Jauch A, Hielscher T, Hillengass J, Raab MS, Seckinger A, Hose D, Ho AD, Goldschmidt H, Neben K. Klein U, et al. Among authors: hillengass j. Cancer. 2011 May 15;117(10):2136-44. doi: 10.1002/cncr.25775. Epub 2010 Dec 4. Cancer. 2011. PMID: 21523726 Free article.

2

[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma].

Moehler TM, Hawighorst H, Neben K, Egerer G, Benner A, Hillengass J, Max R, Ho AD, Goldschmidt H, van Kaick G. Moehler TM, et al. Among authors: hillengass j. Radiologe. 2000 Aug;40(8):723-30. doi: 10.1007/s001170050802. Radiologe. 2000. PMID: 11006943 Clinical Trial. German.

3

Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging.

Moehler TM, Hawighorst H, Neben K, Egerer G, Hillengass J, Max R, Benner A, Ho AD, van Kaick G, Goldschmidt H. Moehler TM, et al. Among authors: hillengass j. Int J Cancer. 2001 Sep;93(6):862-8. doi: 10.1002/ijc.1421. Int J Cancer. 2001. PMID: 11519049

4

High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.

Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H. Neben K, et al. Among authors: hillengass j. Clin Cancer Res. 2001 Sep;7(9):2675-81. Clin Cancer Res. 2001. PMID: 11555579 Clinical Trial.

5

Antiangiogenic therapy in hematologic malignancies.

Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Moehler TM, et al. Among authors: hillengass j. Curr Pharm Des. 2004;10(11):1221-34. doi: 10.2174/1381612043452587. Curr Pharm Des. 2004. PMID: 15078137 Review.

6

[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].

Wasser K, Moehler T, Neben K, Nosas S, Heiss J, Goldschmidt H, Hillengass J, Düber C, Kauczor HU, Delorme S. Wasser K, et al. Among authors: hillengass j. Rofo. 2004 Sep;176(9):1285-95. doi: 10.1055/s-2004-813414. Rofo. 2004. PMID: 15346264 Clinical Trial. German.

7

Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers.

Nosàs-Garcia S, Moehler T, Wasser K, Kiessling F, Bartl R, Zuna I, Hillengass J, Goldschmidt H, Kauczor HU, Delorme S. Nosàs-Garcia S, et al. Among authors: hillengass j. J Magn Reson Imaging. 2005 Jul;22(1):154-62. doi: 10.1002/jmri.20349. J Magn Reson Imaging. 2005. PMID: 15971177

8

Thalidomide in multiple myeloma.

Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H. Moehler TM, et al. Among authors: hillengass j. Curr Pharm Biotechnol. 2006 Dec;7(6):431-40. doi: 10.2174/138920106779116919. Curr Pharm Biotechnol. 2006. PMID: 17168659 Review.

9

Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.

Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, Kauczor HU, Ho AD, Goldschmidt H, Moehler TM. Hillengass J, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):475-81. doi: 10.1158/1078-0432.CCR-06-0061. Clin Cancer Res. 2007. PMID: 17255268

10

Where is the primary tumour?

Zechmann CM, Giesel FL, Hillengass J, Mehndiratta A, Neben K, Delorme S, Moehler T. Zechmann CM, et al. Among authors: hillengass j. Lancet. 2007 Nov 24;370(9601):1800. doi: 10.1016/S0140-6736(07)61747-4. Lancet. 2007. PMID: 18037083 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

205 results

Search Page

Filters